The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning

British Journal of Pharmacology

Volumn 172, Issue 6, 2015, Pages 1587-1606

  Andreadou, Ioanna ^a   Iliodromitis, Efstathios K ^a   Rassaf, Tienush ^b   Schulz, Rainer ^c   Papapetropoulos, Andreas ^a,e   Ferdinandy, Péter ^d  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e PHARMAHUNGARY GROUP   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ALLICIN; ALLYL SULFIDE; APELIN 13; CARBON MONOXIDE; CARBON MONOXIDE DONOR; CARBON MONOXIDE RELEASING MOLECULE; DIAZOXIDE; DICLOFENAC DERIVATIVE; GARLIC OIL; GASOTRANSMITTER; HYDROGEN SULFIDE; ISOFLURANE; MORPHOLIN 4 IUM 4 METHOXYPHENYL MORPHOLINOPHOSPHINODITHIOATE; NCX 6550; NICORANDIL; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; NITRITE ANION; ORGANIC NITRATE; PRAVASTATIN; PROTECTIVE AGENT; S ALLYLCYSTEINE; STROMAL CELL DERIVED FACTOR 1; TRISULPHIDE DIALLYL DISULPHIDE; UNCLASSIFIED DRUG; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; DRUG ACTIVITY; DRUG MECHANISM; EXPERIMENTAL MODEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REMOTE CONDITIONING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; HEART INFARCTION PREVENTION; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CARDIOTONIC AGENTS; GASOTRANSMITTERS; HUMANS; HYDROGEN SULFIDE; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MOLECULAR TARGETED THERAPY; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 84923782340     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12811     Document Type: Review

References (167)

1. Abraham NG, Kappas A, (2008). Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60: 79-127.
2. Ahlström K, Biber B, Åberg AM, Abrahamsson P, Johansson G, Ronquist G, et al. (2011). Exogenous carbon monoxide does not affect cell membrane energy availability assessed by sarcolemmal calcium fluxes during myocardial ischaemia-reperfusion in the pig. Eur J Anaesthesiol 28: 356-362.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Andreadou I, Farmakis D, Prokovas E, Sigala F, Zoga A, Spyridaki K, et al. (2012). Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res 94: 501-509.
6. + (ATP) opener nicorandil in experimental myocardial infarction. Shock 32: 247-252.
7. Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, Cirino G, et al. (2013). Selectivity of commonly used pharmacological inhibitors for cystathionine b synthase (CBS) and cystathionine g lyase (CSE). Br J Pharmacol 169: 922-932.
8. Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, et al. (2007). Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A 104: 17977-17982.
9. Bencsik P, Kupai K, Giricz Z, Görbe A, Pipis J, Murlasits Z, et al. (2010). Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol Heart Circ Physiol 299: H512-H518.
10. Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S, et al. (2006). Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther 316: 670-678.
11. Bliksoen M, Kaljusto ML, Vaage J, Stenslokken KO, (2008). Effects of hydrogen sulphide on ischaemia-reperfusion injury and ischaemic preconditioning in the isolated, perfused rat heart. Eur J Cardiothorac Surg 34: 344-349.
12. Bouhidel JO, Wang P, Li Q, Cai H, (2014). Pharmacological postconditioning treatment of myocardial infarction with netrin-1. Front Biosci 19: 566-570.
13. Bullen ML, Miller AA, Dharmarajah J, Drummond GR, Sobey CG, Kemp-Harper BK, (2011). Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am J Physiol Heart Circ Physiol 301: H1405-H1414.
14. Burley DS, Ferdinandy P, Baxter GF, (2007). Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 152: 855-869.
15. 2S-releasing drugs as pharmaceuticals. J Med Chem 53: 6275-6286.
16. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, et al. (2009). Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105: 365-374.
17. Chatterjee PK, (2004). Water-soluble carbon monoxide-releasing molecules: helping to elucidate the vascular activity of the 'silent killer'. Br J Pharmacol 142: 391-393.
18. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, et al. (1999). Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 39: 93-109.
19. Cheng S, Lyass A, Massaro JM, O'Connor GT, Keaney JF Jr, Vasan RS, (2010). Exhaled carbon monoxide and risk of metabolic syndrome and cardiovascular disease in the community. Circulation 122: 1470-1477.
20. Chin BY, Jiang G, Wegiel B, Wang HJ, Macdonald T, Zhang XC, et al. (2007). Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proc Natl Acad Sci U S A 104: 5109-5114.
21. Chouchani ET, Methner C, Nadtochiy SM, Logan A, Pell VR, Ding S, et al. (2013). Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med 19: 753-759.
22. Chuah SC, Moore PK, Zhu YZ, (2007). S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. Am J Physiol Heart Circ Physiol 293: H2693-H26701.
23. Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, et al. (2003). Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ Res 93: e2-e8.
24. Clark JE, Kottam A, Motterlini R, Marber MS, (2009). Measuring left ventricular function in the normal, infarcted and CORM-3-preconditioned mouse heart using complex admittance-derived pressure volume loops. J Pharmacol Toxicol Methods 59: 94-99.
25. Cohen MV, Yang XM, Downey JM, (2006). Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res 70: 231-239.
26. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Mõdis K, Panopoulos P, et al. (2012). Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U S A 109: 9161-9166.
27. Csonka C, Páli T, Bencsik P, Görbe A, Ferdinandy P, Csont T, (2015). Measurement of NO in biological samples. Br J Pharmacol 172: 1620-1632.
28. Csont T, (2010). Nitroglycerin-induced preconditioning: interaction with nitrate tolerance. Am J Physiol Heart Circ Physiol 298: H308-H309.
29. Csont T, Ferdinandy P, (2005). Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105: 57-68.
30. Czibik G, Sagave J, Martinov V, Ishaq B, Sohl M, Sefland I, et al. (2009). Cardioprotection by hypoxia-inducible factor 1 alpha transfection in skeletal muscle is dependent on haem oxygenase activity in mice. Cardiovasc Res 82: 107-114.
31. Dezfulian C, Raat N, Shiva S, Gladwin MT, (2007). Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res 75: 327-338.
32. Di Filippo C, Monopoli A, Ongini E, Perretti M, D'Amico M, (2010). The cardio-protective properties of Ncx-6550, a nitric oxide donating pravastatin, in the mouse. Microcirculation 17: 417-426.
33. Durante W, (2002). Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med 7: 195-202.
34. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. (2007). Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 104: 15560-15565.
35. Elsey DJ, Fowkes RC, Baxter GF, (2010). L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 15: 53-59.
36. Fan Q, Yang XC, Liu Y, Wang LF, Liu SH, Ge YG, et al. (2011). Postconditioning attenuates myocardial injury by reducing nitro-oxidative stress in vivo in rats and in humans. Clin Sci (Lond) 120: 251-261.
37. Fekete V, Murlasits Z, Aypar E, Bencsik P, Sárközy M, Szénási G, et al. (2013). Myocardial postconditioning is lost in vascular nitrate tolerance. J Cardiovasc Pharmacol 62: 298-303.
38. Ferdinandy P, (2006). Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 148: 1-3.
39. Ferdinandy P, Schulz R, (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543.
40. Ferdinandy P, Schulz R, Baxter GF, (2007). Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
41. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R, (2014). Interaction of cardiovascular risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning: an update. Pharmacol Rev. [in press].
42. Foresti R, Goatly H, Green CJ, Motterlini R, (2001). Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol 281: H1976-H1984.
43. Fu Y, Wang Z, Chen WL, Moore PK, Zhu YZ, (2007). Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol 293: H1545-H1552.
44. Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Auchampach JA, Gross GJ, et al. (2010). Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology 112: 73-85.
45. 2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun 313: 362-368.
46. Gonzales MA, Mascharak PK, (2014). Photoactive metal carbonyl complexes as potential agents for targeted CO delivery. J Inorg Biochem 133: 127-135.
47. Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Luca MC, et al. (2010). Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol 298: H340-H345.
48. Hausenloy DJ, Bøtker HE, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, et al. (2013). Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 98: 7-27.
49. Hendgen-Cotta UB, Merx MW, Shiva S, Schmitz J, Becher S, Klare JP, et al. (2008). Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A 105: 10256-10261.
50. Hendgen-Cotta UB, Flogel U, Kelm M, Rassaf T, (2010a). Unmasking the Janus face of myoglobin in health and disease. J Exp Biol 213: 2734-2740.
51. Hendgen-Cotta UB, Kelm M, Rassaf T, (2010b). A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. Nitric Oxide 22: 75-82.
52. Heusch G, (2013). Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381: 166-175.
53. Heusch G, Boengler K, Schulz R, (2008). Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
54. Hobbs AJ, Fukuto JM, Ignarro LJ, (1994). Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci U S A 91: 10992-10996.
55. Hu LF, Pan TT, Neo KL, Yong QC, Bian JS, (2008b). Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes. Pflugers Arch 455: 971-978.
56. + exchanger activity via stimulation of phosphoinositide 3-kinase/Akt and protein kinase G pathways. J Pharmacol Exp Ther 339: 726-735.
57. Hu Y, Chen X, Pan TT, Neo KL, Lee SW, Khin ES, et al. (2008a). Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 455: 607-616.
58. Huang YE, Tang ZH, Xie W, Shen XT, Liu MH, Peng XP, et al. (2012). Endogenous hydrogen sulfide mediates the cardioprotection induced by ischemic postconditioning in the early reperfusion phase. Exp Ther Med 4: 1117-1123.
59. Huhn R, Heinen A, Weber NC, Hieber S, Hollmann MW, Schlack W, et al. (2009). Helium-induced late preconditioning in the rat heart in vivo. Br J Anaesth 102: 614-619.
60. Issa K, Kimmoun A, Collin S, Ganster F, Fremont-Orlowski S, Asfar P, et al. (2013). Compared effects of inhibition and exogenous administration of Hydrogen sulfide in ischaemia-reperfusion injury. Crit Care 17: R129.
61. Ji Y, Pang QF, Xu G, Wang L, Wang JK, Zeng YM, (2008). Exogenous hydrogen sulfide postconditioning protects isolated rat hearts against ischemia-reperfusion injury. Eur J Pharmacol 587: 1-7.
62. 2S in patients with coronary heart disease. Di Yi Jun Yi Da Xue Xue Bao 25: 951-954.
63. 2S) protects against regional myocardial ischemia-reperfusion injury-evidence for a role of K ATP channels. Basic Res Cardiol 101: 53-60.
64. Johnson RA, Teran FJ, Durante W, Peyton KJ, Johnson FK, (2004). Enhanced heme oxygenase-mediated coronary vasodilation in Dahl salt-sensitive hypertension. Am J Hypertens 17: 25-30.
65. Johnson TR, Mann BE, Teasdale IP, Adams H, Foresti R, Green CJ, et al. (2007). Metal carbonyls as pharmaceuticals? [Ru(CO)3Cl(glycinate)], a CO-releasing molecule with an extensive aqueous solution chemistry. Dalton Trans 21: 1500-1508.
66. Jones SP, Bolli R, (2006). The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40: 16-23.
67. Kashfi K, Olson KR, (2013). Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol 85: 689-703.
68. King AL, Polhemus DJ, Bhushan S, Otsuka H, Kondo K, Nicholson CK, et al. (2014). Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A 111: 3182-3187.
69. Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E, (2013). Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther 27: 359-361.
70. Kondo-Nakamura M, Shintani-Ishida K, Uemura K, Yoshida K, (2010). Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. Biochem Biophys Res Commun 393: 449-454.
71. Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, et al. (2007). Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 27: 1276-1282.
72. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, de Marais W, et al. (2009). Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 297: H1729-H1735.
73. Lee TS, Chang CC, Zhu Y, Shyy JY, (2004). Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110: 1296-1302.
74. Li G, Labruto F, Sirsjö A, Chen F, Vaage J, Valen G, (2004). Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. Eur J Cardiothorac Surg 26: 968-973.
75. Li J, Loukili N, Rosenblatt-Velin N, Pacher P, Feihl F, Waeber B, et al. (2013). Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo. PLoS ONE 8: e70331.
76. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK, (2007). Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 42: 706-719.
77. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, et al. (2008). Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117: 2351-2360.
78. Lin HH, Chen YH, Chiang MT, Huang PL, Chau LY, (2013). Activator protein-2α mediates carbon monoxide-induced stromal cell-derived factor-1α expression and vascularization in ischemic heart. Arterioscler Thromb Vasc Biol 33: 785-794.
79. Lotz C, Lazariotto M, Redel A, Smul TM, Stumpner J, Blomeyer C, et al. (2011). Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo. Exp Biol Med 236: 113-122.
80. Luan HF, Zhao ZB, Zhao QH, Zhu P, Xiu MY, Ji Y, (2012). Hydrogen sulfide postconditioning protects isolated rat hearts against ischemia and reperfusion injury mediated by the JAK2/STAT3 survival pathway. Braz J Med Biol Res 45: 898-905.
81. Lynn EG, Austin RC, (2010). Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. Expert Rev Clin Pharmacol 4: 97-108.
82. Marazioti A, Bucci M, Coletta C, Vellecco V, Baskaran P, Szabõ C, et al. (2011). Inhibition of nitric oxide-stimulated vasorelaxation by carbon monoxide-releasing molecules. Arterioscler Thromb Vasc Biol 31: 2570-2576.
83. Martelli A, Testai L, Breschi MC, Blandizzi C, Virdis A, Taddei S, et al. (2012). Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev 32: 1093-1130.
84. Mei DS, Du YA, Wang Y, (2007). Cardioprotection and mechanisms of exogenous carbon monoxide releaser CORM-2 against ischemia/reperfusion injury in isolated rat hearts. Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 291-297.
85. Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, et al. (2013). Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108: 337.
86. Moncada S, Higgs A, Furchgott R, (1997). International Union of Pharmacology nomenclature in nitric oxide research. Pharmacol Rev 49: 137-142.
87. Motterlini R, Otterbein LE, (2010). The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 9: 728-743.
88. Muchova L, Wong RJ, Hsu M, Morioka I, Vitek L, Zelenka J, et al. (2007). Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 85: 800-810.
89. Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C, (2012). S-nitrosylation: a radical way to protect the heart. J Mol Cell Cardiol 52: 568-577.
90. Münzel T, Gori T, (2013). Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr Opin Pharmacol 13: 251-259.
91. Nagasaka Y, Fernandez BO, Garcia-Saura MF, Petersen B, Ichinose F, Bloch KD, et al. (2008). Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology 109: 675-682.
92. Nagy P, Pálinkás Z, Nagy A, Budai B, Tõth I, Vasas A, (2014). Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim Biophys Acta 1840: 876-891.
93. Neye N, Enigk F, Shiva S, Habazettl H, Plesnila N, Kuppe H, et al. (2012). Inhalation of NO during myocardial ischemia reduces infarct size and improves cardiac function. Intensive Care Med 38: 1381-1391.
94. Nguyen TT, Stevens MV, Kohr M, Steenbergen C, Sack MN, Murphy E, (2011). Cysteine 203 of cyclophilin D is critical for cyclophilin D activation of the mitochondrial permeability transition pore. J Biol Chem 286: 40184-40192.
95. Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, et al. (2006). Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med 41: 106-119.
96. Osipov RM, Robich MP, Feng J, Liu Y, Clements RT, Glazer HP, et al. (2009). Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection. J Cardiovasc Pharmacol 54: 287-297.
97. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. (2010). Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res 87: 406-423.
98. Pacher P, Beckman JS, Liaudet L, (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
99. Pagel PS, (2010). Cardioprotection by noble gases. J Cardiothorac Vasc Anesth 24: 143-163.
100. Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, Weihrauch D, et al. (2007). Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg 105: 562-569.
101. Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, Miranda KM, et al. (2003). Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 34: 33-43.
102. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C, (2011). Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 14: 833-850.
103. Pan TT, Feng ZN, Lee SW, Moore PK, Bian JS, (2006). Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 40: 119-130.
104. 2S preconditioning and post-infarction treatment. Eur J Pharmacol 616: 160-165.
105. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106.
106. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, et al. (2013). Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol 304: H1215-H1224.
107. Peers C, Steele DS, (2012). Carbon monoxide: a vital signalling molecule and potent toxin in the myocardium. J Mol Cell Cardiol 52: 359-365.
108. Penna C, Perrelli MG, Tullio F, Angotti C, Camporeale A, Poli V, et al. (2013). Diazoxide postconditioning induces mitochondrial protein S-nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. Basic Res Cardiol 108: 371.
109. Petrishchev NN, Vlasov TD, Sipovsky VG, Kurapeev DI, Galagudza MM, (2001). Does nitric oxide generation contribute to the mechanism of remote ischemic preconditioning? Pathophysiology 7: 271-274.
110. Peyton KJ, Reyna SV, Chapman GB, Ensenat D, Liu XM, Wang H, et al. (2002). Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood 99: 4443-4448.
111. Predmore BL, Lefer DJ, Gojon G, (2012). Hydrogen sulfide in biochemistry and medicine. Antioxid Redox Signal 17: 119-140.
112. Queiroga CS, Almeida AS, Martel C, Brenner C, Alves PM, Vieira HL, (2010). Glutathionylation of adenine nucleotide translocase induced by carbon monoxide prevents mitochondrial membrane permeabilization and apoptosis. J Biol Chem 285: 17077-17088.
113. Radi R, (2013). Peroxynitrite, a stealthy biological oxidant. J Biol Chem 288: 26464-26472.
114. Rassaf T, Flogel U, Drexhage C, Hendgen-Cotta U, Kelm M, Schrader J, (2007). Nitrite reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res 100: 1749-1754.
115. Rassaf T, Ferdinandy P, Schulz R, (2014). Nitrite in organ protection. Br J Pharmacol 171: 1-11.
116. Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G, et al. (2011). Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 300: H2308-H2315.
117. Rochetaing A, Barbé C, Kreher P, (2001). Acute ischemic preconditioning and high subchronic CO exposure independently increase myocardial tolerance to ischemia. Inhal Toxicol 13: 1015-1032.
118. Romão CC, Blättler WA, Seixas JD, Bernardes GJ, (2012). Developing drug molecules for therapy with carbon monoxide. Chem Soc Rev 41: 3571-3583.
119. Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soldato P, Berti F, (2008). The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart. Br J Pharmacol 153: 100-109.
120. Schulz R, Ferdinandy P, (2013). Does nitric oxide signaling differ in pre- and post-conditioning? Importance of S-nitrosylation vs. protein kinase G activation. Free Radic Biol Med 54: 113-115.
121. Schulz R, Kelm M, Heusch G, (2004). Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 61: 402-413.
122. 2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J Biol Chem 283: 24412-24419.
123. Shahid M, Tauseef M, Sharma KK, Fahim M, (2008). Brief femoral artery ischaemia provides protection against myocardial ischaemia-reperfusion injury in rats: the possible mechanisms. Exp Physiol 93: 954-968.
124. Shi S, Li QS, Li H, Zhang L, Xu M, Cheng JL, et al. (2009). Anti-apoptotic action of hydrogen sulfide is associated with early JNK inhibition. Cell Biol Int 33: 1095-1101.
125. Shinbo T, Kokubo K, Sato Y, Hagiri S, Hataishi R, Hirose M, et al. (2013). Breathing nitric oxide plus hydrogen gas reduces ischemia-reperfusion injury and nitrotyrosine production in murine heart. Am J Physiol Heart Circ Physiol 305: H542-H550.
126. Simon F, Giudici R, Duy CN, Schelzig H, Oter S, Gröger M, et al. (2008). Hemodynamic and metabolic effects of hydrogen sulfide during porcine ischemia/reperfusion injury. Shock 30: 359-364.
127. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, et al. (2009). Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock 31: 267-274.
128. Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN, (2010). The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 9: 119-125.
129. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, et al. (2009). Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. J Thorac Cardiovasc Surg 138: 977-984.
130. Sojitra B, Bulani Y, Putcha UK, Kanwal A, Gupta P, Kuncha M, et al. (2012). Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice. Mol Cell Biochem 360: 61-69.
131. Soni H, Patel P, Rath AC, Jain M, Mehta AA, (2010). Cardioprotective effect with carbon monoxide releasing molecule-2 (CORM-2) in isolated perfused rat heart: role of coronary endothelium and underlying mechanism. Vascul Pharmacol 53: 68-76.
132. Soni HM, Jain MR, Mehta AA, (2012). Mechanism(s) involved in carbon monoxide-releasing molecule-2-mediated cardioprotection during ischaemia-reperfusion injury in isolated rat heart. Indian J Pharm Sci 74: 281-291.
133. 2)S-releasing aspirin. Free Radic Biol Med 46: 586-592.
134. Steensrud T, Li J, Dai X, Manlhiot C, Kharbanda RK, Tropak M, et al. (2010). Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am J Physiol Heart Circ Physiol 299: H1598-H1603.
135. Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, Li Q, et al. (2005). Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol 38: 127-134.
136. Stein AB, Bolli R, Dawn B, Sanganalmath SK, Zhu Y, Wang OL, et al. (2012). Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol 52: 228-236.
137. Sun B, Zou X, Chen Y, Zhang P, Shi G, (2008). Preconditioning of carbon monoxide releasing molecule-derived CO attenuates LPS-induced activation of HUVEC. Int J Biol Sci 4: 270-278.
138. Sun J, Murphy E, (2010). Protein S-nitrosylation and cardioprotection. Circ Res 106: 285-296.
139. Sun WH, Liu F, Chen Y, Zhu YC, (2012). Hydrogen sulfide decreases the levels of ROS by inhibiting mitochondrial complex IV and increasing SOD activities in cardiomyocytes under ischemia/reperfusion. Biochem Biophys Res Commun 421: 164-169.
140. Szabo C, (2010). Gaseotransmitters: new frontiers for translational science. Sci Transl Med 2: 59ps54.
141. Szabo G, Veres G, Radovits T, Gero D, Modis K, Miesel-Groschel C, et al. (2011). Cardioprotective effects of hydrogen sulfide. Nitric Oxide 25: 201-210.
142. Tang YH, Yang JS, Xiang HY, Xu JJ, (2014). PI3K-Akt/eNOS in remote postconditioning induced by brief pulmonary ischemia. Clin Invest Med 37: E26.
143. Tennyson AG, Lippard SJ, (2011). Generation, translocation, and action of nitric oxide in living systems. Chem Biol 18: 1211-1220.
144. Tong G, Aponte AM, Kohr MJ, Steenbergen C, Murphy E, Sun J, (2014). Postconditioning leads to an increase in protein S-nitrosylation. Am J Physiol Heart Circ Physiol 306: H825-H832.
145. Totzeck M, Hendgen-Cotta UB, Luedike P, Berenbrink M, Klare JP, Steinhoff HJ, et al. (2012a). Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 126: 325-334.
146. Totzeck M, Hendgen-Cotta UB, Rammos C, Petrescu AM, Meyer C, Balzer J, et al. (2012b). Assessment of the functional diversity of human myoglobin. Nitric Oxide 26: 211-216.
147. Verma SK, Rajeevan V, Jain P, Bordia A, (2005). Effect of garlic (Allium sativum) oil on exercise tolerance in patients with coronary artery disease. Indian J Physiol Pharmacol 49: 115-118.
148. Wallace JL, Ignarro LJ, Fiorucci S, (2002). Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 1: 375-382.
149. Wang R, (2012). Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 92: 791-896.
150. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A, (2004). Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A 101: 13683-13688.
151. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J, (2011). Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci 121: 459-488.
152. Wu M, Huang Z, Xie H, Zhou Z, (2013). Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE 8: e78231.
153. Yao LL, Huang XW, Wang YG, Cao YX, Zhang CC, Zhu YC, (2010). Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol 298: H1310-H1319.
154. Yao X, Tan G, He C, Gao Y, Pan S, Jiang H, et al. (2012). Hydrogen sulfide protects cardiomyocytes from myocardial ischemia-reperfusion injury by enhancing phosphorylation of apoptosis repressor with caspase recruitment domain. Tohoku J Exp Med 226: 275-285.
155. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, et al. (1999). Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 103: R23-R29.
156. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, et al. (2001). Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 89: 168-173.
157. Yong QC, Lee SW, Foo CS, Neo KL, Chen X, Bian J-S, (2008). Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol 295: H1330-H1340.
158. ATP channels and permeability transition pores of mitochondria in dogs. Cardiovasc Drugs Ther 26: 217-226.
159. Yoshida T, Maulik N, Ho YS, Alam J, Das DK, (2001). H(mox-1) constitutes an adaptive response to effect antioxidant cardioprotection: a study with transgenic mice heterozygous for targeted disruption of the heme oxygenase-1 gene. Circulation 103: 1695-1701.
160. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL, (2006). Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20: 2118-2120.
161. Zhang J, Piantadosi CA, (1992). Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 90: 1193-1199.
162. Zhang WJ, Shi ZX, Wang BB, Cui YJ, Guo JZ, Li B, (2001). Allitridum mimics effect of ischemic preconditioning by activation of protein kinase C. Acta Pharmacol Sin 22: 132-136.
163. Zhang Z, Huang H, Liu P, Tang C, Wang J, (2007). Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening K ATP channels. Can J Physiol Pharmacol 85: 1248-1253.
164. 2S-donors. Bioorg Med Chem 20: 2675-2678.
165. Zhu JC, Shao JL, Ma H, Wang JK, (2008). Interaction between endogenous cystathionine synthase/hydrogen sulfide and heme oxygenase-1/carbon monoxide systems during myocardial ischemic-reperfusion: experiment with rats. macrophage. Zhonghua Yi Xue Za Zhi 88: 3222-3225.
166. Zhuo Y, Chen PF, Zhang AZ, Zhong H, Chen CQ, Zhu YZ, (2009). Cardioprotective effect of hydrogen sulfide in ischemic reperfusion experimental rats and its influence on expression of survivin gene. Biol Pharm Bull 32: 1406-1410.
167. Zobi F, (2013). CO and CO-releasing molecules in medicinal chemistry. Future Med Chem 5: 175-188.